Valuation: Monopar Therapeutics Inc.

Market Cap 83Cr 71Cr 67Cr 61Cr 114.58Cr 7.95TCr 116.86Cr 787.72Cr 306.93Cr 3.98TCr 312.1Cr 305.3Cr 13TCr P/E 2026 *
-44.4x
P/E 2027 * -44.3x
Enterprise Value 71Cr 61Cr 57Cr 52Cr 98Cr 6.82TCr 100.17Cr 675.18Cr 263.07Cr 3.41TCr 267.51Cr 261.69Cr 11TCr EV / Sales 2026 *
-
EV / Sales 2027 * 24.3x
Free-Float
76.63%
Yield 2026 *
-
Yield 2027 * -
1 day-10.47%
1 week-3.50%
Current month+2.34%
1 month-0.22%
3 months+100.87%
6 months+102.71%
Current year+69.80%
1 week 107.78
Extreme 107.78
124.27
1 month 101
Extreme 101
124.82
Current year 50.07
Extreme 50.07
124.82
1 year 29.18
Extreme 29.18
124.82
3 years 1.37
Extreme 1.3695
124.82
5 years 1.37
Extreme 1.3695
124.82
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 01/12/2014
Director of Finance/CFO 54 03/03/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 01/12/2014
Chairman 73 01/12/2014
Director/Board Member 84 01/04/2017
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Fiscal year

Chief Financial Officer

2,963 0.0442%
30/06/26 Fiscal year

Chief Operating Officer

12,817 0.1913%
30/06/26 Fiscal year

Founder

29,830 0.4453%
Change 5-day change 1-year change 3-year change Capi.($)
-10.47%-3.50%+230.89%+3,325.39% 83Cr
+1.14%+3.46%+4.57%+24.14% 5.05TCr
-1.36%+3.15%+479.46%+614.84% 4.6TCr
-2.04%+2.82%+18.13%+91.23% 4.28TCr
+2.72%+5.93%+33.12%+19.66% 4.1TCr
0.00%-3.91%+17.87%+47.98% 3.2TCr
+0.72%+2.62%+32.57%+145.37% 1.7TCr
-1.85%-0.25% - - 1.71TCr
+3.06%+4.63%+7.40%+35.00% 1.43TCr
+0.50%+2.49%+83.90%+46.53% 1.38TCr
Average -0.76%+2.59%+100.88%+483.35% 2.75TCr
Weighted average by Cap. +0.15%+2.39%+104.54%+163.09%

Financials

2026 *2027 *
Net sales - 2.83Cr 2.42Cr 2.26Cr 2.07Cr 3.9Cr 270.43Cr 3.97Cr 27Cr 10Cr 135.44Cr 11Cr 10Cr 449.4Cr
Net income -2.15Cr -1.84Cr -1.72Cr -1.57Cr -2.96Cr -205.4Cr -3.02Cr -20Cr -7.93Cr -102.87Cr -8.06Cr -7.88Cr -341.33Cr -2.66Cr -2.28Cr -2.13Cr -1.95Cr -3.67Cr -254.71Cr -3.74Cr -25Cr -9.83Cr -127.57Cr -9.99Cr -9.78Cr -423.27Cr
Net Debt -12Cr -10Cr -9.5Cr -8.71Cr -16Cr -1.14TCr -17Cr -112.54Cr -44Cr -569.18Cr -45Cr -44Cr -1.89TCr -14Cr -12Cr -12Cr -11Cr -20Cr -1.38TCr -20Cr -136.99Cr -53Cr -692.85Cr -54Cr -53Cr -2.3TCr
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
-
Date Price Change Volume
20/26/20 $110.88 -10.47% 2,08,005
19/26/19 $123.84 +4.02% 4,00,364
18/26/18 $119.05 +2.20% 1,43,385
17/26/17 $116.49 +3.05% 1,71,114
14/26/14 $113.04 +2.38% 1,65,721
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
110.88USD
Average target price
126.31USD
Spread / Average Target
+13.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock